02 October 2009 and who has followed up to see if applicable to humans?
Doesn't anyone have a sense of urgency around stroke?
http://www.alphagalileo.org/ViewItem.aspx?ItemId=61573&CultureCode=en
The antibiotic minocycline may revolutionize the treatment of strokes. A new study, published in the open access journal BMC Neuroscience, describes the safety and therapeutic efficacy of the drug in animal models.
Dr.
Cesar V. Borlongan from the University of South Florida, USA worked
with a team of researchers to test the treatment in laboratory
experiments. He said, “To date, the thrombolytic agent tPA is the only
effective drug for acute ischemic stroke; however, only about 2% of
ischemic stroke patients benefit from this treatment due to its limited
therapeutic window. There is a desperate need to develop additional
neuroprotective strategies. This research is an important step in
rectifying the treatment issues, presenting a new, more effective
treatment for stroke patients”.
Every 5 minutes someone in the UK
has a stroke and stroke currently accounts for almost 10% of deaths
worldwide, claiming more lives than HIV/AIDS. During a stroke, a clot
prevents blood flow to parts of the brain, which can have wide ranging
short-term and long-term implications. This study recorded the effect of
intravenous minocycline in both isolated neurons and animal models
after a stroke had been experimentally induced. At low doses it was
found to have a neuroprotective effect on neurons by reducing apoptosis
of neuronal cells and ameliorating behavioral deficits caused by
stroke.
According to Dr. Borlongan, “The safety and therapeutic
efficacy of low dose minocycline and its robust neuroprotective effects
during acute ischemic stroke make it an appealing drug candidate for
stroke therapy. An on-going phase 1 clinical study funded by the
National Institutes of Health is exploring the use of intravenous
minocycline to treat acute ischemic stroke”.
No comments:
Post a Comment